ADAR1 Capital Management’s Vaxcyte PCVX Stock Holding History

ADAR1 Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.49M	Sell	146,034 -113,103	-44%	-$6.14M	0.39%	61
2026 Q1	$15.1M	Sell	259,137 -56,505	-18%	-$3.07M	0.89%	24
2025 Q4	$14.6M	Buy	315,642 +102,578	+48%	+$4.59M	1.07%	19
2025 Q3	$7.67M	Buy	213,064 +115,032	+117%	+$3.81M	0.72%	36
2025 Q2	$3.19M	Buy	98,032 +85,232	+666%	+$2.79M	0.49%	45
2025 Q1	$483K	Buy	+12,800	New	+$1.02M	0.09%	106
2024 Q4	–	Sell	-10,097	Closed	-$1.15M	–	283
2024 Q3	$1.15M	Sell	10,097 -2,153	-18%	-$194K	0.19%	64
2024 Q2	$925K	Buy	12,250 +10,250	+513%	+$698K	0.17%	68
2024 Q1	$137K	Buy	2,000 +1,900	+1,900%	+$132K	0.03%	134
2023 Q4	$6.28K	Buy	+100	New	+$5.19K	﹤0.01%	141

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ADAR1 Capital Management's PCVX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Vaxcyte (PCVX) stake by 44% in Q2 2026, selling an estimated $6.14M and leaving 146,034 shares worth $8.49M. The position accounts for 0.39% of the portfolio, ranked #61.

ADAR1 Capital Management first reported a position in PCVX in Q4 2023 and has held it in 10 quarters since. The position peaked at $15.1M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

ADAR1 Capital Management held 146,034 shares of Vaxcyte worth $8.49M as of Q2 2026.
ADAR1 Capital Management sold 113,103 Vaxcyte shares in Q2 2026, an estimated $6.14M.
Vaxcyte made up 0.39% of ADAR1 Capital Management's portfolio in Q2 2026, its #61 holding.
ADAR1 Capital Management first reported a position in Vaxcyte in Q4 2023 and has held it in 10 quarters since.
ADAR1 Capital Management's Vaxcyte position peaked at $15.1M in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.